Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin

Molecular Oncology

Volumn 9, Issue 9, 2015, Pages 1799-1814

  Kuang, Yuting ^a,d   El Khoueiry, Anthony ^b   Taverna, Pietro ^c   Ljungman, Mats ^d   Neamati, Nouri ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Combination therapy; DNMT1; Hepatocellular carcinoma; Oxaliplatin; SGI 110

Indexed keywords

DNA METHYLTRANSFERASE 1; EPIDERMAL GROWTH FACTOR; GUADECITABINE; OXALIPLATIN; SOMATOMEDIN; SURVIVIN; ANTINEOPLASTIC AGENT; AZACITIDINE; BIRC5 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; INHIBITOR OF APOPTOSIS PROTEIN; PLATINUM COMPLEX; SGI-110; WNT3A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; LIVER; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG SYNERGISM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER; LIVER NEOPLASMS; MICE; ORGANOPLATINUM COMPOUNDS; SIGNAL TRANSDUCTION; WNT3A PROTEIN;

EID: 84945485095     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.06.002     Document Type: Article

References (60)

1. Abou-Alfa G.K., Capanu M., O'Reilly E.M., Ma J., Chou J.F., Gansukh B., et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J. Hepatol. 2014, 60(2):319-324.
2. Bekaii-Saab T., Markowitz J., Prescott N., Sadee W., Heerema N., Wei L., et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin. Cancer Res. 2009, 15(18):5895-5901.
3. Bodzin A.S., Wei Z., Hurtt R., Gu T., Doria C. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J. Cell. Physiol. 2012, 227(7):2947-2952.
4. Buckley A.F., Burgart L.J., Sahai V., Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am. J. Clin. Pathol. 2008, 129(2):245-251.
5. Cheung C.H., Huang C.C., Tsai F.Y., Lee J.Y., Cheng S.M., Chang Y.C., et al. Survivin - biology and potential as a therapeutic target in oncology. Onco. Targets Ther. 2013, 6:1453-1462.
6. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58(3):621-681.
7. Chuang J.C., Warner S.L., Vollmer D., Vankayalapati H., Redkar S., Bearss D.J., et al. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 2010, 9(5):1443-1450.
8. Desbois-Mouthon C., Baron A., Blivet-Van Eggelpoel M.J., Fartoux L., Venot C., Bladt F., et al. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15(17):5445-5456.
9. Fan H., Lu X., Wang X., Liu Y., Guo B., Zhang Y., et al. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J. Immunol. Res. 2014, 2014. Article ID 371087, 14. 10.1155/2014/371087.
10. Fan H., Zhao Z.J., Cheng J., Su X.W., Wu Q.X., Shan Y.F. Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma. World J. Gastroenterol. 2009, 15(16):2020-2026.
11. Fang F., Munck J., Tang J., Taverna P., Wang Y., Miller D.F., et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin. Cancer Res. 2014, 20(24):6504-6516.
12. Ferlay J.S.I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 2013, International Agency for Research on Cancer, Lyon, France, Available from:. http://globocan.iarc.fr.
13. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379(9822):1245-1255.
14. Gaur S., Chen L., Ann V., Lin W.C., Wang Y., Chang V.H., et al. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. Mol. Cancer 2014, 13:21.
15. Gedaly R., Galuppo R., Daily M.F., Shah M., Maynard E., Chen C., et al. Targeting the Wnt/beta-catenin signaling pathway in liver Cancer stem cells and hepatocellular carcinoma cell lines with FH535. PLoS One 2014, 9(6):e99272.
16. Glasspool R.M., Brown R., Gore M.E., Rustin G.J., McNeish I.A., Wilson R.H., et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br. J. Cancer 2014, 110(8):1923-1929.
17. Graham J.S., Kaye S.B., Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer 2009, 45(7):1129-1136.
18. Hopfner M., Huether A., Sutter A.P., Baradari V., Schuppan D., Scherubl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem. Pharmacol. 2006, 71(10):1435-1448.
19. Huang W.Y., Hsu S.D., Huang H.Y., Sun Y.M., Chou C.H., Weng S.L., et al. MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic. Acids Res. 2015, 43(Database issue):D856-D861.
20. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20(1):85-93.
21. Kelly R.J., Lopez-Chavez A., Citrin D., Janik J.E., Morris J.C. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol. Cancer 2011, 10:35.
22. Labbe E., Lock L., Letamendia A., Gorska A.E., Gryfe R., Gallinger S., et al. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res. 2007, 67(1):75-84.
23. Lachenmayer A., Alsinet C., Savic R., Cabellos L., Toffanin S., Hoshida Y., et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin. Cancer Res. 2012, 18(18):4997-5007.
24. Liu W., Ahmad S.A., Jung Y.D., Reinmuth N., Fan F., Bucana C.D., et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002, 94(4):934-939.
25. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359(4):378-390.
26. Louafi S., Boige V., Ducreux M., Bonyhay L., Mansourbakht T., de Baere T., et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109(7):1384-1390.
27. Matei D., Fang F., Shen C., Schilder J., Arnold A., Zeng Y., et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012, 72(9):2197-2205.
28. Missiaglia E., Donadelli M., Palmieri M., Crnogorac-Jurcevic T., Scarpa A., Lemoine N.R. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 2005, 24(1):199-211.
29. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34(3):267-273.
30. Neumann O., Kesselmeier M., Geffers R., Pellegrino R., Radlwimmer B., Hoffmann K., et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 2012, 56(5):1817-1827.
31. Nishida N., Kudo M., Nagasaka T., Ikai I., Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012, 56(3):994-1003.
32. Noren N.K., Foos G., Hauser C.A., Pasquale E.B. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat. Cell Biol. 2006, 8(8):815-825.
33. O'Dwyer P.J.L.D., Kauh J.S., Fitzgerald D.B., Benson A.B. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern cooperative oncology group's study E1203. J. Clin. Oncol. 2006, 24. Abstract 4143.
34. Park J.G., Lee J.H., Kang M.S., Park K.J., Jeon Y.M., Lee H.J., et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 1995, 62(3):276-282.
35. Paulsen M.T., Veloso A., Prasad J., Bedi K., Ljungman E.A., Magnuson B., et al. Use of Bru-Seq and BruChase-Seq for genome-wide assessment of the synthesis and stability of RNA. Methods 2014, 67(1):45-54.
36. Paulsen M.T., Veloso A., Prasad J., Bedi K., Ljungman E.A., Tsan Y.C., et al. Coordinated regulation of synthesis and stability of RNA during the acute TNF-induced proinflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(6):2240-2245.
37. Psyrri A., Arkadopoulos N., Vassilakopoulou M., Smyrniotis V., Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 2012, 12(10):1347-1357.
38. Qin S., Bai Y., Lim H.Y., Thongprasert S., Chao Y., Fan J., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 2013, 31(28):3501-3508.
39. Roessler S., Jia H.L., Budhu A., Forgues M., Ye Q.H., Lee J.S., et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010, 70(24):10202-10212.
40. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 2000, 24(3):245-250.
41. Selvakumaran M., Amaravadi R.K., Vasilevskaya I.A., O'Dwyer P.J. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin. Cancer Res. 2013, 19(11):2995-3007.
42. Shitani M., Sasaki S., Akutsu N., Takagi H., Suzuki H., Nojima M., et al. Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma. Tumour Biol. 2012, 33(5):1307-1317.
43. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64(1):9-29.
44. Song J., Teplova M., Ishibe-Murakami S., Patel D.J. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science 2012, 335(6069):709-712.
45. Srivastava P., Paluch B.E., Matsuzaki J., James S.R., Collamat-Lai G., Karbach J., et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk. Res. 2014, 38(11):1332-1341.
46. Srivastava P., Paluch B.E., Matsuzaki J., James S.R., Collamat-Lai G., Taverna P., et al. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics 2015, 10(3):237-246.
47. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(43):15545-15550.
48. Suh S.I., Pyun H.Y., Cho J.W., Baek W.K., Park J.B., Kwon T., et al. 5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Lett. 2000, 160(1):81-88.
49. Tang X.X., Robinson M.E., Riceberg J.S., Kim D.Y., Kung B., Titus T.B., et al. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin. Cancer Res. 2004, 10(17):5837-5844.
50. Tellez C.S., Grimes M.J., Picchi M.A., Liu Y., March T.H., Reed M.D., et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int. J. Cancer 2014, 135(9):2223-2231.
51. Tovar V., Alsinet C., Villanueva A., Hoshida Y., Chiang D.Y., Sole M., et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J. Hepatol. 2010, 52(4):550-559.
52. Wang Y., Cardenas H., Fang F., Condello S., Taverna P., Segar M., et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014, 74(17):4922-4936.
53. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45(4):938-947.
54. Yang J.M., Chen W.S., Liu Z.P., Luo Y.H., Liu W.W. Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells. J. Gastroenterol. Hepatol. 2003, 18(3):296-301.
55. Yoo C.B., Jeong S., Egger G., Liang G., Phiasivongsa P., Tang C., et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007, 67(13):6400-6408.
56. Yuzugullu H., Benhaj K., Ozturk N., Senturk S., Celik E., Toylu A., et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol. Cancer 2009, 8:90.
57. Zeng Z.L., Luo H.Y., Yang J., Wu W.J., Chen D.L., Huang P., et al. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin. Cancer Res. 2014, 20(4):1042-1052.
58. Zhang Y., Yang B., Du Z., Bai T., Gao Y.T., Wang Y.J., et al. Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication. World J. Gastroenterol. 2012, 18(17):2043-2052.
59. Zhu A.X., Rosmorduc O., Evans T.R., Ross P.J., Santoro A., Carrilho F.J., et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2015, 33(6):559-566.
60. Zhu A.X., Stuart K., Blaszkowsky L.S., Muzikansky A., Reitberg D.P., Clark J.W., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110(3):581-589.